Seven months after being spun out from its longtime parent company in a $31.5 million private equity infusion, Avon-based In Vitro Sciences has named its first CEO.
IVS’ board of directors announced Friday that Derek M. Larkin would be the new CEO of the company, which offers management services to reproductive endocrinology practices.
Sverica Capital Management spun out IVS from Women’s Health USA last year as part of a national growth strategy that’s since begun in Arizona.
Larkin was previously CEO of in-vitro practice Boston IVF for 12 years, where IVS said he was responsible for tripling that company’s revenue and launching a national chain of centers.
IVS’ senior most leader since the spin-out has been Brian Pskowski, president and chief operating officer.
“We are fortunate to have someone of Derek Larkin’s caliber and experience to lead IVS,” Gregg Osenkowski, a partner at Sverica and a member of the IVS board, said in a statement. “We are in the midst of transformative growth at IVS, and the addition of Derek to an already veteran team will be immensely valuable as we successfully implement our strategy and continue to grow in the market.”
Larkin left Boston IVS last year after it was acquired by United Arab Emirates-based healthcare giant NMC Health plc, which in recent months has been mired in a fraud scandal, the Financial Times reported.
